Insider Trading & Ownership of James E. Flynn

Location
New York, NY
Summary
The estimated net worth of James E. Flynn is at least $2,328,194,988 dollars as of 02 Mar 2026. James E. Flynn is the Director, Director by Deputization, 10%+ Owner of Nuvalent, Inc. and owns shares of Nuvalent, Inc. (NUVL) stock worth about $1.64B. James E. Flynn is the 10%+ Owner of ARS Pharmaceuticals, Inc. and owns shares of ARS Pharmaceuticals, Inc. (SPRY) stock worth about $180.44M. James E. Flynn is the Director, * Director by Deputization, 10%+ Owner of Larimar Therapeutics, Inc. and owns shares of Larimar Therapeutics, Inc. (LRMR) stock worth about $178.03M. James E. Flynn is the *Possible Member of 10% Group, 10%+ Owner of AdaptHealth Corp. and owns shares of AdaptHealth Corp. (AHCO) stock worth about $141.86M. James E. Flynn is the * Possible Member of 10% Group, 10%+ Owner of Mirum Pharmaceuticals, Inc. and owns shares of Mirum Pharmaceuticals, Inc. (MIRM) stock worth about $90.96M. James E. Flynn is the Director, Director by Deputization, 10%+ Owner of CareMax, Inc. and owns shares of CareMax, Inc. stock worth about $54.75M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Bicara Therapeutics Inc. and owns shares of Bicara Therapeutics Inc. (BCAX) stock worth about $23.77M. James E. Flynn is the Director, Director by deputization of Acutus Medical, Inc. and owns shares of Acutus Medical, Inc. stock worth about $4.16M. James E. Flynn is the Possible Member of 10% Group, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $3.97M. James E. Flynn is the *Possible Member of 10% Group, 10%+ Owner of Singular Genomics Systems, Inc. and owns shares of Singular Genomics Systems, Inc. stock worth about $3.89M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Fractyl Health, Inc. and owns shares of FRACTYL HEALTH, INC. (GUTS) stock worth about $2.42M. James E. Flynn is the Director, *Director by Deputization of BiomX Inc. and owns shares of BiomX Inc. (PHGE) stock worth about $2.32M. James E. Flynn is the Possible Member of 10% Group, 10%+ Owner of Xilio Therapeutics, Inc. and owns shares of Xilio Therapeutics, Inc. (XLO) stock worth about $1.9M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Oncology Institute, Inc. and owns shares of Oncology Institute, Inc. (TOI) stock worth about $448.3K.
Signature
/s/ Jonathan Isler, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow James E. Flynn and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • James E. Flynn has 16 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $2,328,194,988.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Nuvalent, Inc. ($1,639,268,060).
  • Past-year value change for that position: -$70,874,975.

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of James E. Flynn

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
NUVL Nuvalent, Inc. Director, Director by Deputization, 10%+ Owner $1,639,268,060 -$70,874,975 -4.1% 24 Nov 2025
SPRY ARS Pharmaceuticals, Inc. 10%+ Owner $180,437,416 -$13,663,151 -7% 27 Jun 2025
LRMR Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner $178,034,870 +$55,000,000 +45% 27 Feb 2026
AHCO AdaptHealth Corp. *Possible Member of 10% Group, 10%+ Owner $141,859,958 08 Mar 2024
MIRM Mirum Pharmaceuticals, Inc. * Possible Member of 10% Group, 10%+ Owner $90,958,032 06 Jun 2022
CMAX CareMax, Inc. Director, Director by Deputization, 10%+ Owner $54,748,317 17 Nov 2023
BCAX Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner $23,774,208 17 Sep 2024
AFIB Acutus Medical, Inc. Director, Director by deputization $4,163,964 27 Jan 2025
PEPG PepGen Inc. Possible Member of 10% Group, 10%+ Owner $3,971,852 10 May 2022
OMIC Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner $3,891,028 01 Jun 2021
GUTS Fractyl Health, Inc. Possible Members of 10% Group, 10%+ Owner $2,419,003 06 Feb 2024
PHGE BiomX Inc. Director, *Director by Deputization $2,321,016 21 Apr 2025
XLO Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner $1,898,994 26 Oct 2021
TOI, DFPH Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner $448,270 12 Nov 2021
FLAC Frazier Lifesciences Acquisition Corp Possible Member of 10% Group, 10%+ Owner 08 Nov 2022
ONCR Oncorus, Inc. Possible Member of 10% Group, 10%+ Owner 28 Dec 2022

Insider Transactions Reported by James E. Flynn:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .